These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 34561288)

  • 21. Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: A retrospective cohort study.
    Souleymane MB; Decroo T; Mamadou S; Soumana A; Lawan IM; Gagara-Issoufou A; Adehossi E; Ortuño-Gutiérrez N; Lynen L; Rigouts L; de Jong BC; Van Deun A; Piubello A
    Int Health; 2023 May; 15(3):258-264. PubMed ID: 35420123
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Bedaquiline: a novel antitubercular drug for multidrug-resistant tuberculosis.
    Nagabushan H; Roopadevi HS
    J Postgrad Med; 2014; 60(3):300-2. PubMed ID: 25121373
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The use of bedaquiline to treat patients with multidrug-resistant tuberculosis and end-stage renal disease: A case report.
    Park S; Lee KM; Kim I; Mok J
    Int J Infect Dis; 2018 Nov; 76():88-90. PubMed ID: 30244076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of tuberculosis: Focus on bedaquiline.
    Chan B; Khadem TM; Brown J
    Am J Health Syst Pharm; 2013 Nov; 70(22):1984-94. PubMed ID: 24173008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. FDA approval of bedaquiline--the benefit-risk balance for drug-resistant tuberculosis.
    Cox E; Laessig K
    N Engl J Med; 2014 Aug; 371(8):689-91. PubMed ID: 25140952
    [No Abstract]   [Full Text] [Related]  

  • 26. Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline.
    Pontali E; D'Ambrosio L; Centis R; Sotgiu G; Migliori GB
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28331046
    [No Abstract]   [Full Text] [Related]  

  • 27. Combating drug-resistant tuberculosis: the unexpected benefits of bedaquiline.
    Furin J; Diacon AH; Andries K
    Int J Tuberc Lung Dis; 2017 Jan; 21(1):4-5. PubMed ID: 28157457
    [No Abstract]   [Full Text] [Related]  

  • 28. Off-Label Use of Bedaquiline in Children and Adolescents with Multidrug-Resistant Tuberculosis.
    Achar J; Hewison C; Cavalheiro AP; Skrahina A; Cajazeiro J; Nargiza P; Herboczek K; Rajabov AS; Hughes J; Ferlazzo G; Seddon JA; du Cros P
    Emerg Infect Dis; 2017 Oct; 23(10):1711-3. PubMed ID: 28758889
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bedaquiline in multidrug-resistant pulmonary tuberculosis GENESIS-SEFH drug evaluation report.
    Borrego Izquierdo Y; López Briz E; Márquez Saavedra E
    Farm Hosp; 2015 Jan; 39(1):1-5. PubMed ID: 25680429
    [No Abstract]   [Full Text] [Related]  

  • 30. Bedaquiline for the treatment of drug-resistant tuberculosis.
    Bélard S; Heuvelings CC; Janssen S; Grobusch MP
    Expert Rev Anti Infect Ther; 2015 May; 13(5):535-53. PubMed ID: 25797824
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bedaquiline: Introducing a new drug to the MDR TB armamentarium.
    Kambili C
    Indian J Tuberc; 2016 Jul; 63(3):137-138. PubMed ID: 27865232
    [No Abstract]   [Full Text] [Related]  

  • 32. Evidence-based Definition for Extensively Drug-Resistant Tuberculosis.
    Roelens M; Battista Migliori G; Rozanova L; Estill J; Campbell JR; Cegielski JP; Tiberi S; Palmero D; Fox GJ; Guglielmetti L; Sotgiu G; Brust JCM; Bang D; Lienhardt C; Lange C; Menzies D; Keiser O; Raviglione M
    Am J Respir Crit Care Med; 2021 Sep; 204(6):713-722. PubMed ID: 34107231
    [No Abstract]   [Full Text] [Related]  

  • 33. Bedaquiline Microheteroresistance after Cessation of Tuberculosis Treatment.
    de Vos M; Ley SD; Wiggins KB; Derendinger B; Dippenaar A; Grobbelaar M; Reuter A; Dolby T; Burns S; Schito M; Engelthaler DM; Metcalfe J; Theron G; van Rie A; Posey J; Warren R; Cox H
    N Engl J Med; 2019 May; 380(22):2178-2180. PubMed ID: 31141643
    [No Abstract]   [Full Text] [Related]  

  • 34. Bedaquiline-Resistant Tuberculosis: Dark Clouds on the Horizon.
    Andres S; Merker M; Heyckendorf J; Kalsdorf B; Rumetshofer R; Indra A; Hofmann-Thiel S; Hoffmann H; Lange C; Niemann S; Maurer FP
    Am J Respir Crit Care Med; 2020 Jun; 201(12):1564-1568. PubMed ID: 32053752
    [No Abstract]   [Full Text] [Related]  

  • 35. Combined treatment of drug-resistant tuberculosis with bedaquiline and delamanid: a systematic review.
    Pontali E; Sotgiu G; Tiberi S; Tadolini M; Visca D; D'Ambrosio L; Centis R; Spanevello A; Migliori GB
    Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29903862
    [No Abstract]   [Full Text] [Related]  

  • 36. Current issues with the use of bedaquiline.
    Kakkar AK; Dahiya N
    Ann Pharmacother; 2014 May; 48(5):666. PubMed ID: 24519480
    [No Abstract]   [Full Text] [Related]  

  • 37. Bedaquiline: a novel antitubercular agent for the treatment of multidrug-resistant tuberculosis.
    Worley MV; Estrada SJ
    Pharmacotherapy; 2014 Nov; 34(11):1187-97. PubMed ID: 25203970
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bedaquiline in multidrug-resistant tuberculosis treatment: Safety and efficacy in a Korean subpopulation.
    Kim JH; Kwon OJ; Kim YS; Park MS; Hwang S; Shim TS
    Respir Investig; 2020 Jan; 58(1):45-51. PubMed ID: 31635903
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rapid emergence of
    Veziris N; Bernard C; Guglielmetti L; Le Du D; Marigot-Outtandy D; Jaspard M; Caumes E; Lerat I; Rioux C; Yazdanpanah Y; Tiotiu A; Lemaitre N; Brossier F; Jarlier V; Robert J; Sougakoff W; Aubry A; ;
    Eur Respir J; 2017 Mar; 49(3):. PubMed ID: 28182568
    [No Abstract]   [Full Text] [Related]  

  • 40. Bedaquiline and delamanid in combination for treatment of drug-resistant tuberculosis.
    Mohr E; Ferlazzo G; Hewison C; De Azevedo V; Isaakidis P
    Lancet Infect Dis; 2019 May; 19(5):470. PubMed ID: 31034392
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.